Progranulin: An emerging target for FTLD therapies
نویسندگان
چکیده
منابع مشابه
Emerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملEmerging Therapies for Atherosclerosis
In the United States alone, about 250,000 people develop significant mitral regurgitation (MR) each year, with almost 50,000 undergoing surgery. Surgical repair of a diseased mitral valve has become the treatment of choice for patients with significant MR. Since there is no single therapeutic approach for every etiology of MR, surgical mitral valve repair includes a variety of techniques that a...
متن کاملEmerging Therapies for Osteoporosis
Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity lik...
متن کاملMelanoma: molecular pathogenesis and emerging target therapies (Review).
Malignant melanoma is an aggressive tumor of the skin with a poor prognosis for patients with advanced disease. It is resistant to current therapeutic approaches. In melanoma, both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms. Mutations of BRAF have been proposed to contribute to melanoma development. Increased ac...
متن کاملAutophagy- An emerging target for melanoma therapy
Melanoma accounts for only 5% of all cancers but is the leading cause of skin cancer death due to its high metastatic potential. Patients with metastatic melanoma have a 10-year survival rate of less than 10%. While the clinical landscape for melanoma is evolving rapidly, lack of response to therapies, as well as resistance to therapy remain critical obstacles for treatment of this disease. In ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Brain Research
سال: 2012
ISSN: 0006-8993
DOI: 10.1016/j.brainres.2012.01.047